Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
226 results about "Oncolytic adenovirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Adenovirus varieties have been explored extensively as a viral vector for gene therapy and also as an oncolytic virus. Of the many different viruses being explored for oncolytic potential, an adenovirus was the first to be approved by a regulatory agency, the genetically modified H101 strain. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer.
Oncolytic adenovirus armed with therapeutic genes
InactiveUS20060147420A1Improve efficiencyBiocideOrganic active ingredientsOncolytic adenovirusNucleotide
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Oncolytic adenovirus
InactiveUS7001596B1Eliminate the effects ofLessBiocideGenetic material ingredientsOncolytic adenovirusNormal cell
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and / or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Owner:ONYX PHARMA INC
Applications of chrysophanol or derivative thereof and oncolytic virus in preparation of antitumor drugs
ActiveCN105456302AImprove anti-tumor effectImprove the effectiveness of treatmentOrganic active ingredientsUnknown materialsOncolytic adenovirusVirology
The invention belongs to the field of biomedicines, and relates to applications of chrysophanol or a derivative thereof and oncolytic virus in preparation of antitumor drugs. The invention finds that chrysophanol or the derivative thereof can be used for preparing oncolytic virus antitumor synergistic agents for the first time. Meanwhile, the invention also relates to a pharmaceutical composition containing chrysophanol and oncolytic virus, a medicine suit containing chrysophanol and oncolytic virus, and applications of chrysophanol and oncolytic virus in treatment of tumors, particularly tumors insensitive to the oncolytic virus.
Owner:GUANGZHOU VIROTECH PHARMA
Oncolytic virus therapy
A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.
Owner:WELLSTAT BIOLOGICS CORP
Chimeric adenoviruses for use in cancer treatment
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Owner:AKAMIS BIO LTD
Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
InactiveUS20070258952A1Minimizing potential cytotoxicityIncrease infectivityBiocideSpecial deliveryOncolytic adenovirusOncogene MYC
The present invention includes compositions and methods for the knockdown of one or more genes to a target cell in need of gene therapy by using an siRNA transgene that is integrated into a replication-competent, oncolytic adenovirus.
Owner:GRADALIS +2
Tmprss2 Regulatory Sequences and Uses Thereof
InactiveUS20070275915A1Selective cytolysisOrganic active ingredientsBiocideOncolytic adenovirusCancer research
The present invention generally relates to substances and methods useful for the treatment of neoplastic disease. More specifically, it relates to cancer selective promoters and their use in oncolytic adenoviral vectors. The oncolytic adenoviral vectors are useful in methods of gene therapy. The promoters and the oncolytic adenoviral vectors are useful in methods for screening for compounds that modulate the expression of the cancer selective genes.
Owner:CELLS GENESYS INC
Oncolytic virus for expression of immune checkpoint modulators
ActiveUS20170157188A1High activityEasy to identifyHydrolasesPharmaceutical delivery mechanismNucleotideOncolytic adenovirus
The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
Owner:TRANSGENE SA
Enhanced adoptive cell therapy
ActiveCN105307671AEnhance the popular effectEasy to handlePeptide/protein ingredientsGenetic material ingredientsAdoptive cellular therapyOncolytic adenovirus
Owner:TILT BIOTHERAPEUTICS OY
Combination of oncolytic virus with immune checkpoint modulators
ActiveUS20170143780A1Antagonize activityEasy to getPeptide/protein ingredientsPharmaceutical delivery mechanismOncolytic adenovirusVirology
The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).
Owner:INSTITUT GUSTAVE ROUSSY +1
Oncolytic adenoviral vectors and methods and uses related thereto
InactiveCN103221423AAddresses issues related to healing resistanceLittle side effectsVectorsPeptide/protein ingredientsTumor reductionOncolytic adenovirus
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing CD40L in a cell and increasing tumor specific immune response and apoptosis in a subject, as well as to uses of the oncolytic adenoviral vector of the invention for producing CD40L in a cell and increasing tumor specific immune response and apoptosis, while decreasing tumor-associated immunosuppression, in a subject.
Owner:ONCOS THERAPEUTICS
Oncolytic adenovirus armed with therapeutic genes
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Oncolytic viruses as phenotyping agents for neoplasms
The present invention provides a method of diagnosing neoplasms having a particular phenotype by using oncolytic viruses that selectively replicate in neoplasms having the particular phenotype. For example, reovirus does not replicate in normal cells. However, reovirus selectively replicate in cells with an activated ras pathway, which leads to death of these cells. Therefore, a cell which becomes neoplastic due to, at least in part, elevated ras pathway activities can be diagnosed by its susceptibility to reovirus replication. This invention can further be applied, using other oncolytic viruses, to the diagnosis and / or treatment of other tumors, such as interferon-sensitive tumors, p53-deficient tumors and Rb-deficient tumors. Kits useful in the diagnosis or treatment disclosed herein are also provided.
Owner:ONCOLYTICS BIOTECH
Oncolytic adenovirus
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and / or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Owner:ONYX PHARMA INC
Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with SS or SA hemoglobin or erythroleukemia cells stably transfected with BCAM / Lu which are capable of selectively localizing in tumor vasculature promoting ischemia and occlusion and carrying oncolytic viruses, antitumor proteins, plasmids, toxins and chemotherapy into the tumor milieu. Nucleated erythroid precursors containing SS or SA hemoglobin and transfected with nucleic acids encoding a hypoxia-responsive element and containing nucleic acids encoding expression of oncolytic viruses, superantigens, toxins, viruses, antitumor proteins and chemotherapy are also useful in inducing a potent and specific tumoricidal response. An especially favored carrier is an SS nucleated erythroid precursor transfected with a replication competent oncolytic adenovirus or self-replicating alphavirus expressing a fusogenic membrane glycoprotein or a tumoricidal polypeptide.
Owner:TERMAN DAVID S +1
Oncolytic adenoviral vectors coding for monoclonal Anti-ctla-4 antibodies
InactiveUS20130243731A1Increased E2F levelImprove the level ofBiocideGenetic material ingredientsOncolytic adenovirusApoptosis
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing monoclonal anti-CTLA4 antibodies in a cell and increasing tumor specific immune response and apoptosis in a subject, as well as uses of the oncolytic adenoviral vectors for producing monoclonal anti-CTLA4 antibodies in a cell and increasing tumor specific immune response and apoptosis in a subject.
Owner:ONCOS THERAPEUTICS
Recombinant serotype 5 (Ad5) adenoviral vectors
Owner:TARGOVAX
Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof
ActiveUS7951585B2Strong specificityIncrease infectivityBiocidePeptide/protein ingredientsOncolytic adenovirusWilms' tumor
The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.
Owner:CHENGDU KANGHONG BIOTECH
Application of IAP inhibitor and oncolytic virus in preparation of antitumor drug
The invention belongs to the field of biological medicines and relates to an application of combination of a Caspase activator and an oncolytic virus in preparation of an antitumor drug. The condition that the antitumor effect of the oncolytic virus can be improved with the Caspase activator is discovered for the first time, the combination of the Caspase activator and the oncolytic virus has a quite high synergistic effect, and an effective therapeutic schedule is provided for oncotherapy with low drug sensitivity.
Owner:GUANGZHOU VIROTECH PHARMA
Vaccine for inducing specific immunity of tumor and application thereof
InactiveCN103110939AEnhance tumor immunityStrong immune responseViral antigen ingredientsUnknown materialsOncolytic adenovirusSpecific immunity
The invention relates to a vaccine comprising an adenovirus vector and a vaccinia virus vector and an application of the vaccine in treating tumor. The vaccine comprises oncolytic adenovirus and vaccinia virus; the two viruses are used in sequence, wherein the oncolytic adenovirus is the reproductive human adenovirus type 5 and the vaccinia virus is the vaccinia virus for smallpox vaccine. According to the vaccine, the oncolytic adenovirus and the vaccinia virus are prepared into the vaccine by sequential combination, so the antineoplastic activity can be improved, the stronger cellular immune response can be generated compared with the effect of reversely associated virus or separate virus, the using effect is better and the long-term specific immunity of tumor is shown. The tumor vaccine can eradicate the tumor and generate the long-term specific immunity of tumor and can be used in the treatment of various tumors of the human or animals; and meanwhile, the vaccine can effectively prevent the tumor from relapsing and has a wide application prospect.
Owner:ZHENGZHOU UNIV +1
Tumour-dissolving adenovirus mutant possessing multiple specific anti-tumour mechanism
InactiveCN1884556AGood curative effectPlay a therapeutic roleFermentationGenetic engineeringHuman tumorReverse transcriptase
This invention involved oncolytic adenovirus mutant with the multiple antitumoral Mec. It belongs to the BME field. The adenovirus mutant Elb-55kDa and Elb-19kDa has missing gene, inserts chimeric promoter composed by the human telomerase reverse transcriptase core sequence and human tumor epidermal growth factor receptor enhancer before the replication required gene Ela codons mEla289R and mEla243R. So the virus can specific proliferate in cancer cell. Oncolytic viruses and mEla protein can exert thire influence. It can also increase the sensitivity of cancer cell to chemoradiation and have no influence to normal cell. It inserts the human h-endostatin gene expression cassette in adenovirus mutant gene group; along the replication of virus in cancer cell to amplificate h-endostatin gene and effective expression in tumor so to restrain neovascularization of tumor so to realize the result of restrain the increase and transformation of cancer cell and apoptotic cell. This new oncolytic adenovirus mutant has good clinical prospect in gene curing so to used in curing many kinds of human tumors.
Owner:JIANGSU SHUNTANG BIOENG
Liver cancer-specific gene-virus and application thereof
InactiveCN102796709AImprove securityGenetic material ingredientsViruses/bacteriophagesOncolytic adenovirusNormal cell
The invention discloses a liver cancer-specific gene-virus and application thereof. The virus is an oncolytic virus; an early gene E1 of the virus is divided into E1A and E1B; a promoter of the E1A is replaced by a liver cancer-specific promoter, and is preferably replaced by a liver cancer-specific alpha fetoprotein promoter; and an anticancer gene is carried by the virus. The anticancer gene is SOCS3, HCCS-1, TSLC-1, 1L-24, MnSOD or TRAIL. The anticancer gene is preferably IL-24. The liver cancer-specific gene-virus is used for specific medicines for treating liver cancer, has a relatively high targeting anti-hepatoma effect, basically does not affect normal cells, and also has a small effect on most of other cancer cells.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Adenoviral vectors and methods and uses related thereto
ActiveUS20100166799A1Enhance immune responseImprove the level ofPeptide/protein ingredientsPeptidesOncolytic adenovirusCancer therapy
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.
Owner:TARGOVAX
Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of Cancer
PendingUS20190142967A1NGF/TNF-superfamilyUnknown materialsAbnormal tissue growthOncolytic adenovirus
Owner:TRIEZA THERAPEUTICS INC
Oncolytic virus construction body, oncolytic virus and application thereof
InactiveCN108728488APrevent proliferationSignificant effectAntibody mimetics/scaffoldsUnknown materialsOncolytic adenovirusTumor specific
The invention provides an oncolytic virus construction body, an oncolytic virus and application thereof. The oncolytic virus construction body comprises a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule encodes a secreted fusion protein molecule; the secreted fusion protein molecule is used for inhibiting immune checkpoints; and the second nucleic acid molecule encodes an immunostimulant molecule. According to the embodiment of the invention, the construction body encodes fusion protein and immunostimulant molecules for inhibiting the immune checkpoints and can inhibit immunosuppression mechanism mediated by the immune checkpoints and immunoreactions which causes individual tumor specificity so as to realize generalized and effectivetumor cell killing.
Owner:LIFESEQ LTDRP
Chimeric adenoviruses for use in cancer treatment
ActiveUS20050265973A1Growth inhibitionBiocidePeptide/protein ingredientsOncolytic adenovirusSerotype
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Owner:AKAMIS BIO LTD
Oncolytic adenoviruses with increased proportion of the 156r splicing isoform of the e1b protein
ActiveUS20150315547A1Improve the level ofIncrease oncolytic activityBiocideGenetic material ingredientsOncolytic adenovirusWild type
The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoformis increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells whilst sparing normal cells.
Owner:IXOGEN
Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
ActiveUS20100047208A1Increase transcriptional activityBetter targeting capabilityBiocidePeptide/protein ingredientsOncolytic adenovirusTumor cells
The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.
Owner:CHENGDU KANGHONG BIOTECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com